AstraZeneca CEO: Explosive Q1 China Growth Will Ease In 2H, Then Reignite
AstraZeneca generated 28% sales growth in China during the first quarter - but the UK group's CEO said that stellar performance will decline somewhat in the second half.
You may also be interested in...
Tagrisso, Lynparza and Imfinzi are enjoying stellar sales growth which is unlikely to slow down any time soon.
Q1 Earnings Preview: When AstraZeneca reports first-quarter results on April 26 investor focus will be on new product sales growth, pipeline catalysts and clues on possible fresh divestment and licensing deals.
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.